{"hands_on_practices": [{"introduction": "Managing large or locally advanced gastrointestinal stromal tumors (GISTs) requires careful strategic planning to balance the goals of complete oncologic resection with the avoidance of excessive surgical morbidity. This exercise challenges you to apply foundational principles of surgical oncology to a common clinical dilemma: a large gastric GIST with potential invasion into the pancreas. You will weigh the options of immediate, aggressive surgery against a neoadjuvant approach using tyrosine kinase inhibitors to determine the optimal management pathway that maximizes the chance of a safe and effective cure. [@problem_id:5126719]", "problem": "A 58-year-old woman presents with 3 weeks of melena and fatigue. Hemoglobin is $9.8\\,\\mathrm{g/dL}$. Contrast-enhanced computed tomography (CT) of the abdomen shows a $9\\,\\mathrm{cm}$ exophytic mass arising from the posterior wall of the proximal stomach, with broad-based contact and loss of fat plane to the anterior surface of the pancreatic body. There is no evidence of distant metastasis or lymphadenopathy. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) demonstrates a spindle-cell neoplasm positive for KIT (CD117) and Discovered On Gastrointestinal stromal tumor 1 (DOG1), consistent with a gastrointestinal stromal tumor (GIST). The patient is hemodynamically stable without ongoing bleeding after resuscitation.\n\nYou must decide between a laparoscopic versus open operative approach as part of an overall oncologic plan. Use the following foundational principles to guide your reasoning: (i) the primary goal of solid tumor surgery is complete macroscopic and microscopic removal with negative margins, denoted R0, while avoiding tumor rupture; (ii) if a malignant tumor is adherent to or invading adjacent organs, en bloc resection of the involved viscera is required to preserve R0 resection and prevent tumor violation; (iii) gastrointestinal stromal tumors rarely spread to lymph nodes, so routine formal lymphadenectomy is not required; (iv) neoadjuvant tyrosine kinase inhibitor (TKI) therapy can downsize KIT-positive GISTs and potentially convert multivisceral resections into less morbid procedures; and (v) minimally invasive approaches are appropriate only when they do not increase the risk of tumor rupture or compromise en bloc resection.\n\nWhich of the following management strategies best reflects appropriate decision-making for operative approach selection in this patient?\n\nA. Proceed with immediate laparoscopic wedge gastrectomy, minimizing manipulation with atraumatic graspers to avoid capsular rupture.\n\nB. Proceed with immediate open partial gastrectomy en bloc with distal pancreatectomy (and splenectomy if required) to achieve R0 resection given suspected pancreatic invasion; no lymphadenectomy.\n\nC. Obtain tissue confirmation (already available), initiate neoadjuvant imatinib for approximately 8–12 weeks, restage to assess separation from the pancreas, and plan an open resection if multivisceral resection remains likely; consider a laparoscopic approach only if post-therapy imaging and intraoperative assessment indicate clear separation and low risk of rupture.\n\nD. Schedule endoscopic submucosal dissection to avoid major surgery, given the submucosal origin and well-circumscribed nature of GISTs.", "solution": "The user has provided a clinical scenario and a set of guiding principles to determine the optimal management strategy for a patient with a gastrointestinal stromal tumor (GIST). I will first validate the problem statement and then proceed to a detailed solution.\n\n### Step 1: Extract Givens\n\n*   **Patient Demographics:** A 58-year-old woman.\n*   **Clinical Presentation:** 3 weeks of melena and fatigue.\n*   **Laboratory Data:** Hemoglobin is $9.8\\,\\mathrm{g/dL}$.\n*   **Imaging Findings (Contrast-enhanced CT):**\n    *   A 9-cm exophytic mass arising from the posterior wall of the proximal stomach.\n    *   The mass has broad-based contact and loss of fat plane with the anterior surface of the pancreatic body.\n    *   No evidence of distant metastasis or lymphadenopathy.\n*   **Pathology (EUS-FNA):**\n    *   Spindle-cell neoplasm.\n    *   Immunohistochemistry: Positive for KIT (CD117) and Discovered On Gastrointestinal stromal tumor 1 (DOG1).\n    *   Diagnosis: Consistent with a gastrointestinal stromal tumor (GIST).\n*   **Patient Status:** Hemodynamically stable without ongoing bleeding after resuscitation.\n*   **Guiding Principles:**\n    *   (i) The primary goal is complete macroscopic and microscopic removal (R0 resection) while avoiding tumor rupture.\n    *   (ii) If a malignant tumor is adherent to or invades adjacent organs, an *en bloc* resection of the involved viscera is required to achieve an R0 resection.\n    *   (iii) GISTs rarely metastasize to lymph nodes, so routine formal lymphadenectomy is not required.\n    *   (iv) Neoadjuvant tyrosine kinase inhibitor (TKI) therapy can downsize KIT-positive GISTs and potentially convert multivisceral resections into less morbid procedures.\n    *   (v) Minimally invasive approaches are appropriate only if they do not increase the risk of tumor rupture or compromise *en bloc* resection.\n\n### Step 2: Validate Using Extracted Givens\n\n*   **Scientific Groundedness:** The problem is scientifically and medically sound. The patient's presentation (melena, anemia), imaging findings (9-cm gastric mass with pancreatic abutment), and pathology (spindle cells positive for CD117 and DOG1) are a classic and coherent representation of a large, high-risk GIST. The provided principles are the established cornerstones of modern GIST management.\n*   **Well-Posedness:** The problem is well-posed. It presents a specific, detailed clinical case and asks for the selection of the best management strategy from a list of options by applying a given set of explicit principles. A unique, optimal solution can be logically derived.\n*   **Objectivity:** The problem statement is objective and uses precise, standard medical terminology. It is free from subjective or biased language.\n*   **Completeness and Consistency:** The problem is self-contained and provides all necessary information to make an informed decision. The given facts (large tumor size, potential pancreatic invasion, KIT-positivity, patient stability) are internally consistent and set up a clear decision-making challenge.\n*   **Realism:** The scenario is highly realistic and represents a complex but common problem in surgical oncology. All data points are plausible.\n\n### Step 3: Verdict and Action\n\nThe problem statement is **valid**. It is scientifically sound, well-posed, objective, and complete. I will now proceed with the derivation of the solution and evaluation of the options.\n\n### Derivation and Option Analysis\n\nThe patient presents with a large (9 cm) GIST. Tumors of this size carry a high risk of malignancy and are often friable, increasing the risk of intraoperative rupture. The key finding on CT is the \"loss of fat plane\" between the tumor and the pancreas, which is highly suggestive of tumor adherence or frank invasion. The patient is hemodynamically stable, meaning there is no emergency requiring immediate surgery, which allows for a considered, multidisciplinary approach. The tumor is confirmed to be KIT-positive, making it a candidate for TKI therapy.\n\nLet's apply the given principles to this scenario:\n\n*   **Principle (i) and (ii):** The surgical goal is an R0 resection. Given the potential pancreatic involvement, an upfront surgery would necessitate an *en bloc* resection of the stomach and the involved part of the pancreas (distal pancreatectomy) to satisfy these principles. This is a major operation with significant morbidity.\n*   **Principle (v):** A minimally invasive (laparoscopic) approach for a 9-cm tumor, especially one that is exophytic and abutting the pancreas, carries an unacceptably high risk of tumor rupture. Tumor rupture leads to peritoneal dissemination and dramatically worsens prognosis. Therefore, an upfront laparoscopic approach is contraindicated by this principle.\n*   **Principle (iii):** Regardless of the surgical approach, a formal lymphadenectomy is not indicated, as GISTs rarely involve lymph nodes.\n*   **Principle (iv):** This principle is central to the decision. Since the tumor is KIT-positive and the patient is stable, there is an opportunity to use neoadjuvant TKI therapy (imatinib is the standard first-line agent). The goals of neoadjuvant therapy are twofold: first, to decrease the tumor size and friability, thereby reducing the risk of intraoperative rupture; and second, to potentially shrink the tumor away from the pancreas, which could convert a required multivisceral resection into a less morbid simple gastrectomy. This ability to de-escalate major surgery without compromising oncologic safety is a key advantage.\n\nBased on this synthesis, the optimal strategy is to leverage neoadjuvant therapy to improve the conditions for a safe and effective surgical resection.\n\nNow, I will evaluate each option based on this reasoning.\n\n**A. Proceed with immediate laparoscopic wedge gastrectomy, minimizing manipulation with atraumatic graspers to avoid capsular rupture.**\nThis option is deeply flawed. A laparoscopic approach for a 9-cm GIST is oncologically hazardous due to the high risk of rupture (violates principle v). Furthermore, a simple wedge gastrectomy completely ignores the high suspicion of pancreatic involvement, making an R0 resection highly unlikely (violates principles i and ii). Minimal manipulation cannot sufficiently mitigate the risk for a tumor of this size and location.\n**Verdict: Incorrect.**\n\n**B. Proceed with immediate open partial gastrectomy en bloc with distal pancreatectomy (and splenectomy if required) to achieve R0 resection given suspected pancreatic invasion; no lymphadenectomy.**\nThis option describes an oncologically sound surgical procedure if immediate surgery were the only choice. It correctly identifies the need for an open approach and an *en bloc* resection to address the pancreatic involvement (honoring principles i, ii, and v) and correctly omits lymphadenectomy (honoring principle iii). However, it fails to consider the significant benefit of neoadjuvant therapy outlined in principle (iv). In a stable patient with a KIT-positive tumor, forgoing the chance to potentially avoid a major pancreatic resection is not the *best* management strategy. It is a valid but suboptimal approach.\n**Verdict: Incorrect.**\n\n**C. Obtain tissue confirmation (already available), initiate neoadjuvant imatinib for approximately 8–12 weeks, restage to assess separation from the pancreas, and plan an open resection if multivisceral resection remains likely; consider a laparoscopic approach only if post-therapy imaging and intraoperative assessment indicate clear separation and low risk of rupture.**\nThis option represents the most sophisticated and appropriate management plan, correctly integrating all provided principles. It leverages the tumor's KIT-positivity to employ neoadjuvant therapy (principle iv) with the explicit goal of downsizing the tumor and de-escalating the required surgery. It correctly establishes a plan to restage after therapy to guide the surgical decision. It defaults to an open resection, the safest approach for a large or adherent tumor (honoring principles i, ii, v), while prudently leaving open the possibility of a minimally invasive approach only if specific, strict criteria for safety are met post-therapy. This strategy maximizes the chances of an R0 resection while minimizing surgical morbidity. The duration of 8–12 weeks reflects a reasonable timeframe to assess initial response before committing to a longer course or proceeding to surgery.\n**Verdict: Correct.**\n\n**D. Schedule endoscopic submucosal dissection to avoid major surgery, given the submucosal origin and well-circumscribed nature of GISTs.**\nThis option is wholly inappropriate. Endoscopic resection techniques are reserved for very small (2 cm), endoluminal GISTs. A 9-cm exophytic tumor that likely penetrates the full thickness of the gastric wall and involves an adjacent organ is an absolute contraindication for endoscopic removal. An attempt would guarantee incomplete resection and tumor spillage (violates principles i, ii, v).\n**Verdict: Incorrect.**", "answer": "$$\\boxed{C}$$", "id": "5126719"}, {"introduction": "Beyond the initial surgical strategy, successful outcomes depend on meticulous perioperative management. This practice delves into the critical details of preparing a GIST patient for surgery, focusing on the interplay between physiological status and the effects of targeted therapy. By analyzing factors like anemia and the pharmacological impact of imatinib on wound healing, you will learn to make evidence-based decisions that directly mitigate the risk of major complications like anastomotic leakage. [@problem_id:5126646]", "problem": "A patient with a biopsy-proven gastrointestinal stromal tumor (GIST) of the mid-jejunum has completed neoadjuvant therapy with imatinib, a tyrosine kinase inhibitor (TKI) targeting v-kit Hardy-Zuckerman 4 Feline Sarcoma Oncogene Homolog (KIT) and platelet-derived growth factor receptor (PDGFR). The tumor has downsized, and segmental resection with primary anastomosis is planned. The patient is otherwise hemodynamically stable, with the following preoperative parameters: hemoglobin $H = 7.2$ g/dL, arterial oxygen saturation $S_{aO_2} = 0.98$, partial pressure of arterial oxygen $P_{aO_2} = 100$ mmHg, and cardiac output $Q = 5.0$ L/min. The last dose of imatinib was taken the morning of admission. Serum albumin is $3.0$ g/dL, and there is no history of corticosteroid use, diabetes mellitus, or renal failure. The operative field is expected to involve minimally inflamed small bowel. The surgeon must decide between stapled and hand-sewn techniques and manage perioperative imatinib and anemia to minimize anastomotic leak risk.\n\nFrom fundamental surgical physiology, anastomotic healing requires adequate tissue perfusion, oxygen delivery, minimal tension, precise apposition, and absence of severe contamination. Pharmacologically, imatinib inhibits PDGFR signaling, with potential effects on fibroblast proliferation and angiogenesis. In the gastrointestinal tract, small bowel anastomoses generally do not require diversion if constructed with optimal perfusion and tension-free alignment.\n\nWhich strategy most appropriately applies an anastomotic risk assessment grounded in first principles of oxygen delivery and wound biology in the context of ongoing imatinib therapy and anemia, and selects a suitable anastomotic technique for this small bowel GIST resection?\n\nA. Optimize preoperative hemoglobin to $H \\approx 10.0$ g/dL, hold imatinib for $24$–$48$ hours preoperatively and resume approximately $7$–$14$ days postoperatively when early wound healing is established, and perform a stapled side-to-side functional end-to-end small bowel anastomosis constructed tension-free without diversion.\n\nB. Proceed without correcting anemia, continue imatinib through the perioperative period to avoid tumor progression, and perform a hand-sewn two-layer end-to-end anastomosis with routine drains, anticipating that suture placement can compensate for impaired healing.\n\nC. Stop imatinib for $6$ weeks preoperatively to eliminate any wound-healing risk, perform a stapled anastomosis, and add a diverting loop ileostomy to protect the anastomosis, with no need to correct preoperative hemoglobin.\n\nD. Maintain imatinib uninterrupted, avoid any primary anastomosis due to suspected impaired healing, exteriorize both bowel ends as stomas, and plan delayed reconstruction after hemoglobin spontaneously increases postoperatively.", "solution": "The task is to identify the most appropriate surgical and perioperative management strategy for a patient undergoing resection of a jejunal gastrointestinal stromal tumor (GIST) after neoadjuvant imatinib therapy. The decision must be grounded in the provided first principles of oxygen delivery, wound biology, pharmacology of imatinib, and surgical technique.\n\n### Step 1: Validation of the Problem Statement\nThe problem provides a detailed clinical scenario with specific physiological data, pharmacological context, and surgical considerations.\n\n**Extracted Givens:**\n-   **Diagnosis:** GIST of the mid-jejunum.\n-   **History:** Successful downsizing with neoadjuvant imatinib.\n-   **Procedure:** Planned segmental resection with primary anastomosis.\n-   **Physiological Parameters:** Hemoglobin $H = 7.2$ g/dL, arterial oxygen saturation $S_{aO_2} = 0.98$, partial pressure of arterial oxygen $P_{aO_2} = 100$ mmHg, cardiac output $Q = 5.0$ L/min.\n-   **Other Factors:** Serum albumin $3.0$ g/dL, no other major comorbidities, minimally inflamed bowel.\n-   **Pharmacology:** Imatinib taken on admission day.\n-   **Fundamental Principles:**\n    1.  Anastomotic healing requires adequate oxygen delivery.\n    2.  Imatinib inhibits PDGFR, potentially impairing fibroblast proliferation and angiogenesis, which are crucial for wound healing.\n    3.  Small bowel anastomoses generally do not require diversion if technically well-constructed.\n\n**Validation Verdict:**\nThe problem is scientifically grounded, well-posed, and objective. It presents a realistic clinical challenge that requires the integration of quantitative physiological assessment with principles of pharmacology and surgery. The data are sufficient and consistent for a rigorous analysis. The problem is therefore **valid**.\n\n### Step 2: Derivation of the Correct Approach from First Principles\n\n**1. Analysis of Oxygen Delivery:**\nThe first principle emphasizes the necessity of adequate oxygen delivery for anastomotic healing. We must quantify the patient's systemic oxygen delivery ($DO_2$).\nThe arterial oxygen content ($C_{aO_2}$) is calculated as the sum of oxygen bound to hemoglobin and oxygen dissolved in plasma:\n$$C_{aO_2} = (H \\times 1.34 \\frac{\\text{mL O}_2}{\\text{g Hb}} \\times S_{aO_2}) + (P_{aO_2} \\times 0.003 \\frac{\\text{mL O}_2}{\\text{dL} \\cdot \\text{mmHg}})$$\nSubstituting the patient's values:\n$$C_{aO_2} = (7.2 \\text{ g/dL} \\times 1.34 \\times 0.98) + (100 \\text{ mmHg} \\times 0.003)$$\n$$C_{aO_2} \\approx 9.46 \\text{ mL O}_2/\\text{dL} + 0.3 \\text{ mL O}_2/\\text{dL} = 9.76 \\text{ mL O}_2/\\text{dL}$$\nSystemic oxygen delivery ($DO_2$) is the product of cardiac output ($Q$) and arterial oxygen content, with a unit conversion factor of $10$:\n$$DO_2 = Q \\times C_{aO_2} \\times 10 \\frac{\\text{dL}}{\\text{L}}$$\n$$DO_2 = 5.0 \\text{ L/min} \\times 9.76 \\text{ mL O}_2/\\text{dL} \\times 10 = 488 \\text{ mL O}_2/\\text{min}$$\nA normal resting $DO_2$ for an adult is approximately $1000$ mL/min. The calculated value of $488$ mL/min is severely reduced, indicating a profound deficit in oxygen-carrying capacity due to anemia ($H = 7.2$ g/dL). Such a low $DO_2$ significantly compromises the metabolic demands of wound healing, placing the anastomosis at high risk for ischemia and failure. Therefore, correcting the anemia to a safer level, such as $H \\approx 10.0$ g/dL, is a critical preoperative intervention.\n\n**2. Analysis of Imatinib Management:**\nThe second principle highlights imatinib's potential to impair wound healing by inhibiting platelet-derived growth factor receptor (PDGFR), which is important for angiogenesis and fibroblast activity. Continuing the drug without interruption maximizes this risk. Conversely, an excessively long cessation (e.g., many weeks) is inappropriate as it risks tumor progression, defeating the purpose of the neoadjuvant therapy. A balanced approach is required. The half-life of imatinib is ~18 hours and its major active metabolite is ~40 hours. Holding the drug for a short period (e.g., 24–48 hours to a few days) before surgery allows for partial washout. Resuming it postoperatively, after the initial inflammatory and proliferative phases of wound healing are underway (typically after day 7), strikes a balance between minimizing anastomotic risk and maintaining oncologic control. A resumption window of 7–14 days is a common and prudent clinical practice.\n\n**3. Analysis of Surgical Technique:**\nThe third principle states that routine diversion is unnecessary for well-constructed small bowel anastomoses. The operative field involves the mid-jejunum and minimally inflamed tissue, which are factors associated with a low risk of leakage. Therefore, creating a stoma (either diverting or as end stomas) is overly aggressive and not indicated. Both stapled and hand-sewn anastomoses are standard and considered equivalent in efficacy for small bowel reconstruction. A stapled side-to-side functional end-to-end anastomosis is a widely used, safe, and efficient method that ensures a large luminal diameter.\n\n### Step 3: Option-by-Option Analysis\n\n**A. Optimize preoperative hemoglobin to $H \\approx 10.0$ g/dL, hold imatinib for $24$–$48$ hours preoperatively and resume approximately $7$–$14$ days postoperatively when early wound healing is established, and perform a stapled side-to-side functional end-to-end small bowel anastomosis constructed tension-free without diversion.**\nThis option correctly identifies and addresses all key risk factors.\n-   **Anemia:** It correctly prioritizes the optimization of hemoglobin to improve oxygen delivery ($DO_2$), directly adhering to the first principle.\n-   **Imatinib:** It proposes a balanced management plan that mitigates wound healing risk without undue risk of tumor progression, consistent with the second principle.\n-   **Surgical Technique:** It selects a standard, effective technique and correctly avoids an unnecessary stoma, consistent with the third principle.\n**Verdict: Correct**\n\n**B. Proceed without correcting anemia, continue imatinib through the perioperative period to avoid tumor progression, and perform a hand-sewn two-layer end-to-end anastomosis with routine drains, anticipating that suture placement can compensate for impaired healing.**\nThis option is flawed on multiple counts.\n-   It fails to correct the severe anemia, ignoring the critical requirement for adequate oxygen delivery.\n-   It continues imatinib, maximizing its negative impact on wound healing.\n-   It makes the biologically false claim that surgical technique can overcome severe physiological and pharmacological impairment.\n**Verdict: Incorrect**\n\n**C. Stop imatinib for $6$ weeks preoperatively to eliminate any wound-healing risk, perform a stapled anastomosis, and add a diverting loop ileostomy to protect the anastomosis, with no need to correct preoperative hemoglobin.**\nThis option demonstrates poor judgment in multiple domains.\n-   The 6-week hold of imatinib is excessive and poses a significant risk of tumor progression.\n-   It fails to correct the anemia, a primary risk factor for anastomotic leak.\n-   It proposes a diverting stoma, which is not indicated for a low-risk small bowel anastomosis and adds unnecessary morbidity.\n**Verdict: Incorrect**\n\n**D. Maintain imatinib uninterrupted, avoid any primary anastomosis due to suspected impaired healing, exteriorize both bowel ends as stomas, and plan delayed reconstruction after hemoglobin spontaneously increases postoperatively.**\nThis option represents an extreme and unwarranted deviation from standard surgical practice.\n-   It continues imatinib, a key error.\n-   It opts for a highly morbid procedure (double stoma) instead of managing the identified risks (anemia, drug timing).\n-   It relies on passive, unreliable management of anemia (\"spontaneously increases\").\n**Verdict: Incorrect**\n\nBased on a rigorous application of the provided first principles, option A is the only strategy that constitutes a comprehensive, rational, and appropriate plan for this patient.", "answer": "$$\\boxed{A}$$", "id": "5126646"}, {"introduction": "Evaluating the response of GISTs to targeted therapy is more nuanced than for tumors treated with conventional chemotherapy. Because tyrosine kinase inhibitors often induce cytostatic effects and decrease tumor viability without significant size reduction, traditional size-based criteria can be misleading. This exercise will allow you to apply and contrast the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) with the GIST-specific Choi criteria, which incorporate changes in tumor density on CT scans as a surrogate for response. [@problem_id:5126644]", "problem": "A patient with a biopsy-proven Gastrointestinal Stromal Tumor (GIST) begins targeted therapy and undergoes baseline and first follow-up imaging with Computed Tomography (CT). A single target lesion was identified at baseline with the following measurements: longest axial diameter $10$ cm and mean attenuation $80$ Hounsfield Units (HU) on a portal venous phase acquisition. On first follow-up after $12$ weeks, the same lesion measures a longest axial diameter of $8$ cm and mean attenuation of $40$ HU on a technically matched acquisition (same scanner and phase), with no new lesions and no unequivocal progression of non-target disease.\n\nUse the following well-established criteria:\n- Response Evaluation Criteria in Solid Tumors (RECIST) version $1.1$: for a single target lesion, a partial response is defined as at least a $30$ percent decrease in the longest diameter relative to baseline, progressive disease is defined as at least a $20$ percent increase in the longest diameter relative to the smallest prior value (with an absolute increase of at least $0.5$ cm), complete response requires disappearance of all target lesions, and stable disease is assigned if none of the foregoing are met.\n- Choi criteria for GIST on CT: partial response is defined as at least a $10$ percent decrease in unidimensional size or at least a $15$ percent decrease in mean attenuation (in HU), provided there are no new lesions or obvious progression of nonmeasurable disease; complete response requires disappearance of all lesions; progressive disease is defined as at least a $10$ percent increase in size that does not simultaneously meet partial response by attenuation or the appearance of new lesions; otherwise, stable disease is assigned.\n\nDefine the fractional change in a measurement as $(\\text{follow-up} - \\text{baseline}) / \\text{baseline}$. Compute:\n1. The fractional change in longest diameter.\n2. The fractional change in mean attenuation.\n3. A numeric code for the RECIST $1.1$ response category using the mapping $\\{ \\text{complete response} \\rightarrow 0,\\ \\text{partial response} \\rightarrow 1,\\ \\text{stable disease} \\rightarrow 2,\\ \\text{progressive disease} \\rightarrow 3 \\}$.\n4. A numeric code for the Choi response category using the same mapping as above.\n\nExpress the two fractional changes as decimal numbers without a percent sign. Round the fractional changes to three significant figures. Report your final result as a single row matrix in the order: [fractional diameter change, fractional attenuation change, RECIST code, Choi code]. The response codes are unitless; the fractional changes are dimensionless decimals.", "solution": "We are asked to evaluate response after therapy in a Gastrointestinal Stromal Tumor (GIST) using standardized imaging criteria. The foundational steps involve:\n- Computing proportional (fractional) change using the definition $(\\text{follow-up} - \\text{baseline}) / \\text{baseline}$.\n- Applying Response Evaluation Criteria in Solid Tumors (RECIST) version $1.1$ rules to the unidimensional longest diameter because there is a single target lesion and no new lesions.\n- Applying Choi criteria, which consider both unidimensional size and mean attenuation (in Hounsfield Units (HU)).\n\nGiven baseline longest diameter $= 10$ cm and follow-up longest diameter $= 8$ cm, the fractional change in diameter is\n$$\n\\Delta_{\\text{diameter}} = \\frac{8 - 10}{10} = \\frac{-2}{10} = -0.2.\n$$\nRounding to three significant figures yields $-0.200$.\n\nGiven baseline mean attenuation $= 80$ HU and follow-up mean attenuation $= 40$ HU, the fractional change in attenuation is\n$$\n\\Delta_{\\text{attenuation}} = \\frac{40 - 80}{80} = \\frac{-40}{80} = -0.5.\n$$\nRounding to three significant figures yields $-0.500$.\n\nNext, classify by RECIST version $1.1$. For a single target lesion:\n- Complete response requires disappearance of all target lesions; this is not satisfied, as a measurable lesion remains at $8$ cm.\n- Partial response requires at least a $30$ percent decrease in longest diameter relative to baseline. The fractional change is $-0.2$, corresponding to a $20$ percent decrease in size. Since $| -0.2 | = 0.2  0.3$, partial response is not met.\n- Progressive disease requires at least a $20$ percent increase from the smallest prior value with an absolute increase of at least $0.5$ cm. The lesion decreased, so this is not met.\n- Therefore, stable disease applies.\n\nMapping to the specified numeric codes $\\{ \\text{complete response} \\rightarrow 0,\\ \\text{partial response} \\rightarrow 1,\\ \\text{stable disease} \\rightarrow 2,\\ \\text{progressive disease} \\rightarrow 3 \\}$, the RECIST code is $2$.\n\nFinally, classify by Choi criteria:\n- Complete response requires disappearance of all lesions; not met.\n- Partial response is achieved if there is at least a $10$ percent decrease in unidimensional size or at least a $15$ percent decrease in mean attenuation, provided there are no new lesions or obvious progression of nonmeasurable disease. Here, the unidimensional size decreased by $20$ percent (fractional change $-0.2$) and attenuation decreased by $50$ percent (fractional change $-0.5$). Both meet the partial response thresholds. There are no new lesions and no unequivocal progression of non-target disease by the problem’s conditions, so partial response applies.\n- Progressive disease and stable disease do not apply because partial response criteria are satisfied.\n\nUsing the same mapping, the Choi code is $1$.\n\nThus, assembling the results in the requested order and rounding the fractional changes to three significant figures, we have the row matrix:\n$$\n\\begin{pmatrix}\n-0.200  -0.500  2  1\n\\end{pmatrix}.\n$$", "answer": "$$\\boxed{\\begin{pmatrix}-0.200  -0.500  2  1\\end{pmatrix}}$$", "id": "5126644"}]}